The dedicated, prospective design to investigate the role of the vWF/ADAMTS13 axis and complement activation, in order to clarify the issue of COVID-19 coagulopathy as a possible secondary TMA, is the main strength of our study. This evidence concerns the gene ADAMTS13 and blood coagulation disease.